Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

Acquisition

7 Mar 2006 07:04

Marchpole Holdings PLC07 March 2006 FOR IMMEDIATE RELEASE 7 March 2006 Marchpole Holdings plc ("Marchpole") MARCHPOLE COMPLETES ACQUISITION OF MODA AMERICA LLC Marchpole Holdings plc, which designs, produces and sells high quality clothingand accessories for six world class brands (Yves Saint Laurent, Boateng,Jean-Charles de Castelbajac ("JCC") and Jean-Charles de Castelbajac / Rossignol,Emanuel Ungaro and Ungaro), today announces the successful completion of itsacquisition of the whole of the issued share capital of Moda America LLC. Moda America is the US licensee for Emanuel Ungaro and the acquisition bringsfive key benefits : - Based on turnover of $20m in the year to 31st December 2005, primarily from major blue chip U.S. retail customers such as Federated, Macy's, Robinson May and Marshall Fields, the Directors anticipate that sales and margins will increase as Moda benefits from Marchpole's design, sourcing and production base. - Marchpole will be launching the diffusion Ungaro homme collection in the UK from Spring/Summer 2007. This collection will be priced at similar levels to the current YSL ranges which the Directors expect to have significant mass market appeal across Marchpole's existing customer base. - The presence of Marchpole in North America and the new distribution relationships accessed through this acquisition will facilitate the launch of the Jean Charles de Castelbajac brands in the US from Autumn/Winter 2006. - Marchpole's relationship with Emanuel Ungaro has been strengthened further, illustrated by the granting of womenswear distribution rights for the US. - The Emanuel Ungaro mainline collection, already established by Marchpole in Europe and Asia, will now be launched into the US, Canada and South America. Total consideration for the acquisition will be $5.5m in cash, to be satisfiedfrom the Company's existing resources, of which $1.0m was paid on completion andthe balance of $4.5m payable on 31st July 2006. Current Trading Outlook With the third quarter now complete and deliveries underway for the new Spring/Summer 2006 collections, the Directors remain confident of the Company meetingmarket expectations of profit before taxation for the current financial year of£5.0m. In addition, the Directors are intending to implement proposals to enable theCompany to buy-in its issued share capital subject to shareholder approval asthey believe that the current share price undervalues the Company and does notadequately reflect the strong future prospects of the business. Chairman Chris Phillips commented: "The acquisition contributes significantly to our strategic objective ofbecoming a truly worldwide manager of luxury brands". For further information contact: MarchpoleGreg Tufnell - Chief Executive 020 7908 7700 BuchananTim Thompson / Nicola Cronk 020 7466 5000 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
4th May 20177:00 amRNSInitiation of BPS-804 Phase 2b study
28th Apr 20173:37 pmRNSHolding(s) in Company
28th Apr 201712:53 pmRNSHolding(s) in Company
28th Apr 201710:05 amRNSHolding(s) in Company
26th Apr 20177:00 amRNSConversion of loan note and issue of equity
24th Apr 20176:07 pmRNSHolding(s) in Company
5th Apr 20177:00 amRNSGrant of Options and Awards
3rd Apr 20177:00 amRNSResults of Placing
31st Mar 20175:54 pmRNSResults of Placing
29th Mar 201712:30 pmRNSProposed Placing
15th Mar 20177:00 amRNSPosting of Annual Report and Notice of AGM
7th Mar 20177:00 amRNSPositive recommendation for BGS-649 Phase 2b trial
27th Feb 20177:00 amRNSPreliminary Results
20th Feb 20177:00 amRNSEMA Adaptive Pathways programme accepts BPS-804
23rd Jan 20177:05 amRNSPresentation at Shares Spotlight Evening
23rd Jan 20177:00 amRNSThree abstracts accepted for ATS Meeting
12th Jan 20177:01 amRNSDirectorate update
5th Jan 201712:00 pmRNSMereo BioPharma to Present at Biotech Showcase
12th Dec 20167:00 amRNSBusiness Update
7th Nov 20167:10 amRNSAppointment of Chief Financial Officer
3rd Nov 20167:00 amRNSPositive Phase 1 interaction study with BCT-197
5th Oct 20167:00 amRNSDirectorate Change
16th Sep 20167:00 amRNSHalf-year Report
9th Aug 20164:04 pmRNSNotice of Results
18th Jul 20161:25 pmRNSResult of AGM
30th Jun 20167:00 amRNSBPS-804 granted EU orphan drug status
24th Jun 201612:47 pmRNSNotice of AGM
9th Jun 20161:17 pmRNSDirector/PDMR Shareholding
9th Jun 20168:01 amRNSFirst Day of Dealings on AIM
10th Nov 20086:21 pmRNSFurther re financial position
4th Nov 20083:01 pmRNSStatement re suspension
4th Nov 20083:00 pmRNSSuspension
23rd Oct 20084:35 pmRNSHolding(s) in Company
23rd Oct 20082:25 pmRNSAGM Statement
2nd Oct 20083:14 pmRNSHolding(s) in Company
23rd Sep 200810:02 amRNSNotice of AGM
1st Sep 200810:06 amRNSHolding(s) in Company
29th Aug 20083:20 pmRNSResult of GM and Interim Mana
26th Aug 200810:13 amRNSHolding(s) in Company
19th Aug 20082:22 pmRNSHolding(s) in Company
14th Aug 20084:23 pmRNSHolding(s) in Company
13th Aug 200811:00 amRNSDirectorate Change
8th Aug 200811:14 amRNSHolding(s) in Company
8th Aug 200811:03 amRNSHolding(s) in Company
7th Aug 20084:46 pmRNSHolding(s) in Company
6th Aug 20084:41 pmRNSSecond Price Monitoring Extn
6th Aug 20084:36 pmRNSPrice Monitoring Extension
6th Aug 20083:17 pmRNSDirector/PDMR Shareholding
6th Aug 20087:08 amRNSFundraising and New Board App
6th Aug 20087:05 amRNSNew Joint Venture

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.